Sector
PharmaceuticalsOpen
₹895Prev. Close
₹888.25Turnover(Lac.)
₹2,761.63Day's High
₹897.2Day's Low
₹88052 Week's High
₹1,324.352 Week's Low
₹855.1Book Value
₹185.62Face Value
₹1Mkt Cap (₹ Cr.)
88,860.52P/E
20.46EPS
43.46Divi. Yield
0.3417 May 2024
12:00 AM
Dividend
Dividend Amount: 3
Record Date: 26 Jul, 2024
17 May 2024
12:00 AM
AGM
Announcement Date: 17 May, 2024
11 Mar 2025
12:00 AM
Board Meeting
Agenda : Audited Result
The deal is subject to signing a put option agreement, share purchase agreements and other relevant contracts for acquisition of controlling shareholding of Amplitude Surgical SA, directly or through Zydus' affiliates.
The approval is valid for all Zydus Lifesciences affiliates and subsidiaries, said the company in the stock exchange filing dated March 10, 2025.
The approved strengths are 20 mg, 50 mg, 70 mg, 80 mg, 100 mg and 140 mg.
Here are some of the stocks that may see significant price movement today: TCS, Wipro, Zydus Lifesciences, RPP Infra Projects, etc.
The US market is a key growth driver for the company, accounting for almost 47% of Zydus Lifesciences' revenue.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 100.6 | 101.2 | 102.4 | 102.4 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 15,615.9 | 13,538.2 | 13,138.1 | 12,642.1 |
Net Worth | 15,716.5 | 13,639.4 | 13,240.5 | 12,744.5 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 7,981.9 | 7,780 | 6,347.4 | 5,809.9 |
yoy growth (%) | 2.59 | 22.56 | 9.25 | 79.83 |
Raw materials | -2,870.2 | -2,351.4 | -1,951.7 | -1,695.7 |
As % of sales | 35.95 | 30.22 | 30.74 | 29.18 |
Employee costs | -1,204.9 | -1,147.3 | -1,077.4 | -826 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 1,483.2 | 1,876 | 1,609.7 | 1,497.2 |
Depreciation | -478.7 | -451.1 | -428.9 | -293.1 |
Tax paid | -306 | -212.3 | -204.1 | -406.4 |
Working capital | 607.49 | 991.9 | 1,239 | 1,462.2 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 2.59 | 22.56 | 9.25 | 79.83 |
Op profit growth | -16.91 | 62.23 | -13.55 | 412.7 |
EBIT growth | -16.88 | 5.6 | 18.09 | 138.95 |
Net profit growth | -41.88 | 4.48 | 29.52 | 64.79 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 19,021.5 | 16,877.8 | 14,827.6 | 14,125 | 13,812.1 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 19,021.5 | 16,877.8 | 14,827.6 | 14,125 | 13,812.1 |
Other Operating Income | 525.9 | 359.6 | 282.3 | 278.5 | 441 |
Other Income | 307.1 | 186.6 | 2,583.1 | 45.6 | 113.9 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,683.45 | 128.24 | 4,04,012.02 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,620.45 | 71.97 | 1,49,188.03 | 594 | 0.53 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,461.9 | 25.36 | 1,18,041 | 1,438.15 | 0.89 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,056.05 | 56.74 | 1,03,507.2 | 485 | 0.92 | 2,330 | 222.38 |
Dr Reddys Laboratories Ltd DRREDDY | 1,107.95 | 17.83 | 92,443.89 | 849.4 | 0.72 | 4,997.8 | 322.46 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Pankaj R Patel
Managing Director
Sharvil P Patel
Non Executive Director
Mukesh M Patel
Independent Director
Apurva S Diwanji
Whole-time Director
Ganesh N Nayak
Independent Director
Bhadresh K Shah
Company Sec. & Compli. Officer
Dhaval N Soni
Independent Director
Akhil A. Monappa
Independent Director
Upasana Konidela.
Independent Director
Shelina P. Parikh
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Zydus Lifesciences Ltd
Summary
Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products. The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh.Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996. The Companys operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulk durgs, diagnostics, herbal products, skin care products and OTC products. In the year 1996, the Company made a strategic alliance with Gulin Pharma of China and launched Falcigo in India, which is an anti-malarial segment. In May 2000, the company acquired formulation business of Recon Ltd, which strengthens the company in the southern market. In the year 2001, they acquired German Remedies which was the largest M&A in the Indian Pharmaceutical sector and in the same year, they entered into a joint venture with US based Onconova for collaborative
Read More
What is the Zydus Lifesciences Ltd share price today?
The Zydus Lifesciences Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹883.1 today.
What is the Market Cap of Zydus Lifesciences Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Zydus Lifesciences Ltd is ₹88860.52 Cr. as of 13 Mar ‘25
What is the PE and PB ratio of Zydus Lifesciences Ltd?
The PE and PB ratios of Zydus Lifesciences Ltd is 20.46 and 5.00 as of 13 Mar ‘25
What is the 52 Week High and Low of Zydus Lifesciences Ltd?
The 52-week high/low is the highest and lowest price at which a Zydus Lifesciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Zydus Lifesciences Ltd is ₹855.1 and ₹1324.3 as of 13 Mar ‘25
What is the CAGR of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd's CAGR for 5 Years at 28.55%, 3 Years at 34.20%, 1 Year at -8.83%, 6 Month at -21.05%, 3 Month at -9.75% and 1 Month at -6.34%.
What is the shareholding pattern of Zydus Lifesciences Ltd?
The shareholding pattern of Zydus Lifesciences Ltd is as follows:
Promoters - 74.98 %
Institutions - 18.18 %
Public - 6.84 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
